WCK 5222（头孢吡肟-齐多夫定）对中性粒细胞减少症小鼠大腿感染模型中多药耐药菌的疗效。
Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model.
机构信息
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00233-19. Print 2019 Jul.
Abstract
We describe the efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant (meropenem MICs 8 to >256 μg/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 μg/ml. Substantial WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, -1.62 ± 0.58 log CFU/thigh), and a lack of activity was observed with cefepime monotherapy.
摘要
我们描述了人源模拟药物 WCK 5222（头孢吡肟-齐他培南）针对多种耐药性（美罗培南 MIC 值为 8 至 >256μg/ml）在中性粒细胞减少的鼠大腿感染模型中的疗效。WCK 5222 的 MIC 值范围为 4 至 32μg/ml。所有分离株均显示出显著的 WCK 5222 活性，进一步增强了齐他培南单独使用在 16 个分离株中的 11 个（WCK 5222 平均减少量，-1.62±0.58 log CFU/大腿）的疗效，而头孢吡肟单药治疗则没有活性。
相似文献
1
Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant in the Neutropenic Murine Thigh Infection Model.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00233-19. Print 2019 Jul.
2
Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
J Antimicrob Chemother. 2020 Jan 1;75(1):149-155. doi: 10.1093/jac/dkz414.
3
Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
J Antimicrob Chemother. 2021 Aug 12;76(9):2310-2316. doi: 10.1093/jac/dkab183.
4
Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01931-18. Print 2019 Jan.
5
Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00948-18. Print 2018 Nov.
6
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00072-17. Print 2017 May.
7
In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
J Antimicrob Chemother. 2021 Mar 12;76(4):993-1000. doi: 10.1093/jac/dkaa551.
8
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21.
9
Comparative Evaluation of the Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant .
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01669-19.
10
Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02193-20.
引用本文的文献
1
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
2
In Vivo Activity Profiling of Biosynthetic Darobactin D22 against Critical Gram-Negative Pathogens.
ACS Infect Dis. 2024 Dec 13;10(12):4337-4346. doi: 10.1021/acsinfecdis.4c00687. Epub 2024 Nov 20.
3
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
Ann Clin Microbiol Antimicrob. 2023 Jul 5;22(1):55. doi: 10.1186/s12941-023-00606-x.
4
Novel Antimicrobial Agents for Gram-Negative Pathogens.
Antibiotics (Basel). 2023 Apr 16;12(4):761. doi: 10.3390/antibiotics12040761.
5
Biochemical exploration of β-lactamase inhibitors.
Front Genet. 2023 Jan 17;13:1060736. doi: 10.3389/fgene.2022.1060736. eCollection 2022.
6
Drug development concerning metallo-β-lactamases in gram-negative bacteria.
Front Microbiol. 2022 Sep 15;13:959107. doi: 10.3389/fmicb.2022.959107. eCollection 2022.
7
In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
J Antimicrob Chemother. 2022 Jun 29;77(7):1931-1937. doi: 10.1093/jac/dkac110.
8
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.
Antibiotics (Basel). 2022 Feb 20;11(2):277. doi: 10.3390/antibiotics11020277.
9
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Microbiol Spectr. 2022 Feb 23;10(1):e0267821. doi: 10.1128/spectrum.02678-21.
10
Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.
mBio. 2021 Feb 16;12(1):e03058-20. doi: 10.1128/mBio.03058-20.
本文引用的文献
1
Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01931-18. Print 2019 Jan.
2
Assessment of the Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00948-18. Print 2018 Nov.
3
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00682-18. Print 2018 Aug.
4
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
J Med Chem. 2018 May 10;61(9):4067-4086. doi: 10.1021/acs.jmedchem.8b00091. Epub 2018 Apr 20.
5
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. doi: 10.1093/jac/dkx050.
6
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02529-16. Print 2017 Jun.
7
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00072-17. Print 2017 May.
8
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. doi: 10.1017/ice.2016.174. Epub 2016 Aug 30.
9
Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306. doi: 10.1128/AAC.01989-12. Epub 2013 May 6.
10
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.
Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):441-51. doi: 10.1586/erp.10.49.
Zotero 插件